Abstract
Introduction
6-mercaptopurine (6-MP) is a main component of childhood acute lymphoblastic leukemia (ALL) therapy. The sensitivity of 6-MP is associated with genetic variant of 6-MP metabolism. Recently, the NUDT15 genetic variant has been identified as a risk factor of 6-MP intolerability, and its association with 6-MP-induced toxicities and 6-MP dose in ALL patients have been reported. The frequency of NUDT15 hypomorphic variant is higher in Asian populations than in European and African populations. However, the 6-MP tolerable dose and efficacy for NUDT15-deficient patients remains clear. Our study aimed to evaluate 6-MP tolerable dose, the frequencies of 6-MP induced toxicities, and outcome in 17 ALL patients with NUDT15-deficient genotype.
Methods
We genotyped NUDT15 genetic variants and evaluated the patients with NUDT15 homozygous variant in Japanese childhood ALL. The NUDT15 variants V18_V19insGV, V18I, R139C, and R139H were genotyped by Sanger sequencing, and the diplotype was precisely determined. The standard initiation dose of maintenance therapy was 6-MP 40 to 50 mg/m2/day and methotrexate 25 mg/m2/week. The 6-MP-induced toxicities were graded by CTCAE version 4.0. The survival rate was estimated by the log-rank test.
Results
A total of 17 patients with NUDT15 diplotype of *2/*2, *2/*3, *2/*5, *3/*3, *3/*5, and *5/*5 were genotyped as NUDT15 deficient. Fifteen patients were B cell-precursor (BCP) ALL and 2 patients were T-ALL. Of the 15 BCP ALL patients, 13 were standard risk and 2 were high risk patients according to National Cancer Institute/Rome criteria. Grade 3 leukopenia and grade 4 neutropenia were observed in all 17 patients, and the median observation time were 33 (range 3-95) days and 35 (20-137) days after initiating maintenance therapy, respectively. Grade 3 ALT elevation was observed in 6 patients (35%), and median observation time was 47 (range 19-427) days after initiating maintenance therapy. Moreover, during the early consolidation phase with 6-MP, severe myelosuppression was observed in 11 of these patients. The average 6-MP dose during maintenance therapy was 7.0 (range 2.7-18.3) mg/m2/day. Moreover, 16 of these 17 patients (94%) with NUDT15 deficiency required median 66 (range 5-376) days of therapy interruption. Notably, the average 6-MP dose was 18.3 mg/m2/day, and no therapy interruption occurred during maintenance therapy in patients with NUDT15 *5/*5 diplotype. Therefore, the degree of NUDT15 deficiency influenced 6-MP tolerable dose.
The effect of NUDT15 deficiency on treatment outcome was evaluated in 14 patients, who completed treatment. Three patients relapsed at 124-388 days, and two of these three patients died at 877 and 959 days after the end of maintenance therapy, respectively. The overall and event-free survival rate at 4 years were 0.75 and 0.63, respectively. Neither the average 6-MP dose nor the interruption duration was associated with these events.
Conclusions
NUDT15-deficient genotypes strongly influence intolerability. Patients with NUDT15 deficiency did not tolerate standard 6-MP dose, and physicians should consider reducing 6-MP dose to 7 mg/m2 to avoid therapy interruption. Conversely, NUDT15 *5/*5 genotype displayed only mild NUDT15 deficiency, and the patients with this genotype tolerated 40% of the standard 6-MP dose. Further large-scale studies should be conducted to assess the NUDT15 variant's effect on survival.
Figure. Figure.
Disclosures
No relevant conflicts of interest to declare.
Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia